News & Updates
Showing Multidisciplinary articles
Showing

High marks for modified-release oral PDE4 inhibitor in moderate-to-severe psoriasis
The modified-release formulation of novel oral phosphodiesterase-4 (PDE4) inhibitor orismilast shows therapeutic potential in adults with moderate-to-severe psoriasis, with high rates of clinical response as compared with placebo, according to data from the phase IIb IASOS trial presented at AAD 2023.

Oral JAK inhibitor makes headway in alopecia areata
Patients with severe alopecia areata (patchy baldness) had a dramatic hair regrowth, without serious adverse events, when treated with an investigational Janus kinase (JAK) inhibitor in the phase III THRIVE-AA2 study presented at AAD 2023.

QUARTZ3 data make a case for using ivarmacitinib in atopic dermatitis
Treatment with the oral highly selective JAK1 inhibitor ivarmacitinib appears to help reduce disease activity in patients with moderate-to-severe atopic dermatitis (AD), with up to 42 percent of them having complete or near-complete clearance of involved skin areas, according to the results of the pivotal phase III QUARTZ3 trial presented at AAD 2023.





